News
Important Only
Vicarious Surgical Narrows Loss in Q2
Key PointsEPS (Non-GAAP) loss of $2.23 per share was narrower than expected, beating analyst estimates by 10.8%.Operating expenses decreased 24%, driven by reductions across research and development, general and administrative, and sales and marketing.Cash and investments declined to $24.0 million, ...The Motley Fool
Wed, Aug 13
Armata Posts 59 Percent Q2 Revenue Jump
Key Points- GAAP revenue was $2.2 million, outpacing the $1.38 million GAAP consensus estimate due to strong grant and award funding.- Net loss widened significantly to $0.45 per share (GAAP).- Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-...The Motley Fool
Wed, Aug 13
Hyliion Posts Q2 Revenue Miss and Delay
Key PointsGAAP revenue for Q2 2025 reached $1.5 million, missing the analyst estimate of $1.6 million (GAAP) and driven entirely by research and development services for the U.S. Navy.Driven by higher research and development expenses.Hyliion halved its 2025 GAAP revenue forecast to $5–10 million an...The Motley Fool
Wed, Aug 13
Verrica Posts Profit in Fiscal Q2
Key PointsEarnings per share of $0.25 (Non-GAAP) exceeded expectations and marked a return to profitability, boosted by a major milestone payment.Operating expenses sharply declined, with Selling, general, and administrative expenses decreased by 46% (GAAP) compared to the same period in 2024. Resea...The Motley Fool
Wed, Aug 13
Pixelworks Posts Narrower Loss in Q2
Key PointsGAAP revenue of $8.3 million for Q2 2025 narrowly missed analyst expectations and declined 2.4% year-over-year on a GAAP basis.Non-GAAP EPS loss of ($1.00) for Q2 2025 beat estimates by 10.7%, reflecting improved cost discipline.Margin pressure persisted, but adjusted EBITDA loss and non-G...The Motley Fool
Wed, Aug 13
Luminar Posts 5 Percent Sales Drop
Key PointsGAAP revenue for Q2 2025 was $15.6 million, missing analyst consensus estimates, reflecting a 5% year-over-year decline and underperforming the $17.3 million consensus estimate.Non-GAAP EPS loss of $(1.49) came in below expectations, missing the non-GAAP $(1.18) estimate and showing a year...The Motley Fool
Wed, Aug 13
Erasca Narrows Loss 46% in Fiscal Q2
Key PointsNet loss (GAAP) narrowed sharply to $33.9 million in Q2 2025, compared to $63.2 million in Q2 2024.Cash and investments (GAAP) totaled $386.7 million as of Q2 2025, and are projected to fund operations into the second half of 2028.Research and development expenses (GAAP) fell 35.8% in Q2 2...The Motley Fool
Wed, Aug 13
HK Movers | Tencent Music Soars 17% After It Beats Second-Quarterly Estimates as Content Expansion Boosts Demand
TME-SW beat estimates for second-quarter revenue on Tuesday as an expanded content library drove higher user engagement and robust subscriber growth in its online music services.Tiger News
Wed, Aug 13
Theravance Sales Jump 83 Percent
Key PointsRevenue (GAAP) grew 83.2% year over year to $26.2 million in Q2 2025, Revenue (GAAP) exceeded analyst expectations by approximately $0.27 million.Net income (GAAP) reached $54.8 million, driven mainly by a one-time $75.1 million gain from the TRELEGY royalty asset sale.YUPELRI collaboratio...The Motley Fool
Wed, Aug 13
Absci Sales Fall 54 Percent
Key PointsGAAP revenue was $0.6 million for Q2 2025, missing GAAP revenue estimates by 52.3% and Revenue for the three months ended June 30, 2025, was $0.6 million, compared to $1.3 million in the same period of 2024.Research and development spending rose 34% to $20.5 million for the three months en...The Motley Fool
Wed, Aug 13
NeuroPace Revenue Jumps 22 Percent in Q2
Key PointsGAAP revenue rose 22.0% to $23.5 million in Q2 2025, outpacing GAAP estimates by $0.43 million.Gross margin climbed to 77.1%, leading to a raised full-year gross margin outlook of 75% to 76% for FY2025.Operating expenses increased 22.5% year-over-year, primarily driven by one-time personne...The Motley Fool
Wed, Aug 13
Pulse Biosciences Cash Jumps in Q2
Key PointsTotal GAAP costs and expenses, including research and development as well as general and administrative expenses, increased 73.5% year over year for the three months ended June 30, 2025.Cash and cash equivalents climbed to $106.3 million as of Q2 2025, providing a significant runway despit...The Motley Fool
Wed, Aug 13
Nexgel Revenue Jumps 100% in Fiscal Q2
Key PointsGAAP revenue rose 100.3% year over year to $2.88 million in Q2 2025 but missed analyst expectations by 6.5% (GAAP).Gross margin (GAAP) improved significantly to 43.6%, reflecting the impact of branded consumer products and higher utilization.Management maintained full-year 2025 revenue gui...The Motley Fool
Wed, Aug 13
ProKidney Reports 78 Percent Gain in Q2
Key PointsThe Phase 2 REGEN-007 trial for rilparencel demonstrated a 78% reduction in the annual decline of kidney function (eGFR slope), according to topline results reported in July 2025; no serious safety issues reported.The cash runway is projected to extend into mid-2027, aligning with the expe...The Motley Fool
Wed, Aug 13
Zevra Revenue Jumps 486 Percent in Q2
Key PointsGAAP revenue rose to $25.9 million in Q2 2025, exceeding estimates by 14.8%, on strong MIPLYFFA sales and French EAP expansion.GAAP net income reached $74.7 million in Q2 2025, reversing a loss from the prior year, but was fueled by a one-off PRV sale.OLPRUVA performance lagged, prompting ...The Motley Fool
Wed, Aug 13
Fractyl Health Posts 62% Wider Q2 Loss
Key PointsNet loss (GAAP) widened 62% to $27.9 million compared to Q2 2024, as research and development spending rose 26% over the prior year period.No revenue was reported this quarter, in line with expectations.Clinical programs advanced, with full enrollment in pivotal Revita trial cohorts and in...The Motley Fool
Wed, Aug 13
Lineage Cell Revenue Doubles in Q2
Key PointsGAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024.Net loss (GAAP) increased sharply due to large non-recurring impairment and warrant revaluation charges, overshado...The Motley Fool
Wed, Aug 13
Citius Oncology Beats Fiscal Q3 EPS
Key PointsGAAP loss per share of ($0.08) for Q3 FY2025 beat analyst expectations by $0.07No revenue was reported for Q3 FY2025, as LYMPHIR has not yet launched commercially.These 10 stocks could mint the next wave of millionaires › Citius Oncology (NASDAQ:CTOR), a biopharmaceutical company focused o...The Motley Fool
Wed, Aug 13
Kopin Revenue Drops 31% in Fiscal Q2
Key PointsRevenue (GAAP) for Q2 FY2025 missed expectations, coming in 19.6% below analyst estimates, representing a 30.9% decrease from Q2 2024 to $8.5 million (GAAP).Earnings per share (GAAP) were ($0.03) for Q2 FY2025, missing the analyst-predicted GAAP loss of ($0.01) for Q2 2025.Defense sector r...The Motley Fool
Wed, Aug 13
